Now I would think, and I would be pleased to have your comments on this, that there is an argument to be made on the manufacturing side where a compounder is making a significant quantity of a compounded product to then be sold, as opposed to the pharmaceutical side where a pharmacist is compounding one product for one prescription.
Blunt discusses the need for oversight in compounding pharmacies versus traditional manufacturing.
Share
More from Roy Blunt
Senator Blunt's longstanding promise of expanding the reach and resources of the Nation's Registry has saved thousands of lives.
The subcommittee is in recess until 10:00 a.m. on Thursday, May 7. Thank you all.
I have been Chairman twice--let's see, I was Chairman, then Senator Shelby was Chairman, then I was Chairman again.
They decided to change the rules. I suspect that changes the Senate in fundamental ways forever.
Other voices in this conversation
